Xintela
0.29
SEK
-7.64 %
XINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-7.64%
-30.62%
-46.79%
+12.4%
+7.01%
+2.84%
-76.9%
-88.36%
-87.41%
www.xintela.se/investerare
Xintela is active in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.
Revenue
80K
EBIT %
-71,550 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
XINT
Daily low / high price
0.284 / 0.308
SEK
Market cap
164.94M SEK
Turnover
176.7K SEK
Volume
610K
Latest videos
Financial calendar
Annual report
28.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Flerie Invest AB | 55.5 % | 55.5 % |
| Avanza Pension | 5.4 % | 5.4 % |
| AB Svedala Finans | 1.5 % | 1.5 % |
| Per Åke Oldentoft | 1.3 % | 1.3 % |
| Evy Lundgren-Åkerlund | 1.2 % | 1.2 % |
| Nordnet Pensionsförsäkring | 1.1 % | 1.1 % |
| Derek Gregory Batcheller | 0.8 % | 0.8 % |
| Jan Ivar Nordqvist | 0.8 % | 0.8 % |
| Mats Hellström | 0.6 % | 0.6 % |
| Inger Lundgren | 0.5 % | 0.5 % |
ShowingAll content types
Xintela AB Interim Report January - September 2024
Xintela's main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Xintela presents new preclinical results of XSTEM treatment on would healing and skin regeneration at cell therapy conference
Västra Hamnen Market Focus: Xintela: Activities below the surface
Xintela AB Interim Report January – June 2024
Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients
Xintela extends clinical study with XSTEM on knee osteoarthritis patients
Västra Hamnen Market Focus: Xintela: Closing in on the first license agreement
Xintela AB Interim Report January - March 2024
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses
Xintela AB publishes Annual Report 2023
